Frequently Asked Questions
Find answers to some of our most common questions, from the basics about T1D to questions on participating in a research study.
Type 1 diabetes (T1D)
If you live in the United States, it takes 4-6 weeks to get your screening results. Outside of the US, it takes a little longer to allow for shipping. TrialNet forwards all samples from screenings and studies to specialized laboratories across the US. This way, all samples are processed in a consistent way, meeting strict requirements for scientific research. The process takes a little longer, but it's an important step to ensuring that you receive the most accurate results.
If you live in the United States, it takes 4-6 weeks to get your screening results. Outside of the US, it takes a little longer to allow for shipping. TrialNet forwards all samples from screenings and studies to specialized laboratories across the US. This way, all samples are processed in a consistent way, meeting strict requirements for scientific research. The process takes a little longer, but it's an important step to ensuring that you receive the most accurate results.
If you live in the United States, it takes 4-6 weeks to get your screening results. Outside of the US, it takes a little longer to allow for shipping. TrialNet forwards all samples from screenings and studies to specialized laboratories across the US. This way, all samples are processed in a consistent way, meeting strict requirements for scientific research. The process takes a little longer, but it's an important step to ensuring that you receive the most accurate results.
TrialNet is eager to consider novel agents, combinations and study designs that help advance our mission. We accept suggestions for clinical studies, including proof of mechanism, pilot studies, and Phase 1 thru 3 trials. More
Ideas for Mechanistic StudiesTrialNet samples constitute a resource made available to investigators. Our mechanistic portfolio includes studies using samples from previous and ongoing clinical trials, as well as from our TrialNet Pathway to Prevention (TN01) and Long Term Investigational Follow-up (TN16 LIFT) studies. More
Ongoing TrialNet Studies
| ID | Study Name | Description |
|---|---|---|
| TN01 | Pathway to Prevention | T1D Risk Screening of antibody positive individuals |
| TN07 | Oral Insulin Prevention Study | Placebo controlled randomized trial of 7.5mg daily oral insulin |
| TN10 | Anti-CD3 Prevention Study | Placebo controlled randomized trial of 14 course treatment |
| TN16 | Long Term Follow-Up | Study of individuals previously followed in TN01 |
| TN18 | Abatacept Prevention Study | Placebo controlled randomized trial of 1 yr treatment of abatacept |
| TN19 | ATG/GCSF Study | Three arm placebo controlled randomized trial of ATG with or without... |
| TN20 | Immune Effects of Oral Insulin | Randomized trial of 65.5mg of daily or 500mg every other week... |
How can we help you?
Abatacept Prevention Study
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
Meet the Eyth Family
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
University of Helsinki
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
University of Minnesota
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
Mater Medical Research Institute
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
Vita-Salute San Raffael University
We are testing the drug abatacept (CTLA-4Ig) to see if it can delay or prevent early T1D (stage 1) ... individuals newly diagnosed (stage 3), those who took abatacept had improved insulin production and delayed insulin loss...
